Research Paper: Comparing Comorbid Profile and the Pattern of Non-psychiatric Medicine Use Between Elderly and Non-elderly Patients With Schizophrenia

Arash Mirabzadeh1,2, Gita Sadighi2,*, Ahmadali Akbari Kamrani1, Mohammadreza Khodaei Ardakani1,2, Golnaz Feyzzadeh1, Mercedeh Samiei2

1. Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2. Department of Psychiatry, School of Rehabilitation Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
3. Department of Clinical Science, Aging Research Center, School of Rehabilitation Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

* Corresponding Author:
Gita Sadighi, MD.
Address: Department of Psychiatry, School of Rehabilitation Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Tel: +98 (912) 5396837
E-mail: gita.sadighi2018@gmail.com; gi.sadighi@uswr.ac.ir

Objectives: Patients with schizophrenia receive psychiatric medications for many years, and their comorbid profile in old age remains unclear. Moreover, their pattern of non-psychiatric medicine use is of importance. Rehabilitation is crucial in patients with schizophrenia because it improves their strengths and life skills to live independently. These issues are essential in terms of polypharmacy among them, and its associated adverse effects.

Methods: The present cross-sectional study investigated 131 patients with schizophrenia referring to Razi Hospital who were selected by a convenience sampling method. The subjects’ medical records were evaluated in terms of comorbid disorders and non-psychiatric medicine use patterns. Their demographic data were also collected by a separate questionnaire.

Results: The frequency of schizophrenia disorder was higher in males aged ≥65 years. The comorbidity frequency of non-psychiatric disorders was significantly higher in the elderly, compared to non-elderly patients. The most prevalent comorbid disorders in the elderly were musculoskeletal, cardiovascular, and metabolic disorders; and in the non-elderly neurological, hematological, and digestive diseases. The prevalence of non-psychiatric medicine intake was significantly higher in the elderly. The prevalence of non-psychiatric medicine use in the elderly (e.g. aspirin, heart disease medications, hypertension medications, etc.) and non-elderly patients (e.g. anemia medications, antibiotics, anticonvulsants, etc.) was not similar.

Discussion: In schizophrenic patients, the old age period is associated with more comorbid disorders, compared to their healthy counterparts. Such comorbid profile is similar to other patients; e.g. the most prevalent comorbidities were musculoskeletal, cardiovascular, and metabolic disorders. Polypharmacy is a medical problem in the elderly, with numerous adverse effects. The adjunct consumption of psychiatric medications with the non-psychiatric ones highlights the vital phenomena of drug interactions and associated adverse effects of polypharmacy.
Highlights

- In schizophrenia patients, the old age is associated with more comorbid disorders.
- The most prevalent comorbidities in schizophrenic patients are musculoskeletal, cardiovascular, and metabolic disorders.
- Polypharmacy is a medical problem in the elderly, with numerous adverse effects.
- The adjunct consumption of psychiatric medications with the non-psychiatric ones highlights the vital phenomena of drug interactions and associated adverse effects of polypharmacy.

Plain Language Summary

Old age is a risk factor in patients with schizophrenia, because compared with the younger patients they may have other mental and physical problems. The most common diseases among older patients with schizophrenia are musculoskeletal, cardiovascular, and metabolic disorders. Using different medications concurrently is a problem in older people, leading to many side effects, which should be considered by the healthcare staff.

1. Introduction

Schizophrenia disorder is characterized by acute episodes, that often consequence with improved symptoms [1]. Schizophrenia in the elderly population is categorized by either an early onset, and middle-age or old age experienced symptoms (early-onset schizophrenia), or late-onset type (the disease must be initiated in later life; i.e. the age of 45 years or above) [2]. Moreover, rehabilitation is crucial in patients with schizophrenia, because it improves their strengths and life skills to live independently. On the other hand, according to the World Health Organization (WHO), 7 out of every 1000 adult individuals, mostly in the age group of 15-35 years suffer from schizophrenia [2].

Various biopsychological disorders are often accompanied by schizophrenia. The odds of developing such conditions are higher among the elderly. Moreover, there are greater chances of hypertension, obesity, type 2 diabetes, and dyslipidemia development in patients suffering from schizophrenia [3]. Evidence suggests the increasing survival of elderly patients with mental illnesses, which will probably continue growing in the future. However, research studies highlighted the age-related health issues in this population, including cognitive impairments [4].

As a result, schizophrenic patients receive a high amount of antipsychotic drugs for a significant proportion of their lifetime; numerous adverse effects are associated with such long-term pharmacotherapy. Thus, investigating its prevalence and related clinical factors in patients suffering from schizophrenia is inevitable [5]. However, data on such issues in patients suffering from this disease in old ages are limited, and most investigators focused on the young sufferers. The available data on the long-term risk-benefit ratio in patients with schizophrenia receiving antipsychotic treatment is controversial.

Some studies investigated the long-term effects of antipsychotics [1]. The elderly population is at higher risk for the adverse effects of antipsychotics such as metabolic syndrome, falls, and parkinsonism. Prior research has extensively reported the desirable effects and safety of antipsychotics on schizophrenia middle-aged and old patients. However, some scholars determined that these medications induced various side effects in the aforementioned age groups (both serious and mild) [6].

Significant critical gaps exist in the comorbidity disorders and polypharmacy effects in older patients suffering from schizophrenia. Therefore, the present research was conducted to address such issues by determining the comorbid profile and the pattern of non-psychiatric medicine use between elderly and non-elderly patients with schizophrenia. The result of the present research may provide further information for the development of novel strategies in the treatment of these patients.

2. Methods

The present cross-sectional study was performed at Razi Hospital, Tehran City, Iran, in 2019. A total of 395 pa-
tients were selected by a convenience sampling method. The samples were then divided into two groups of elderly (males: 76; females: 55) and non-elderly (males: 196, females: 68) patients with schizophrenia. The elderly population comprised of all patients aged ≥65 years, and the non-elderly group consisted of patients aged ≤65 years (the participants of the two groups were matched with each other). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Also, informed consent was obtained from all study participants. The inclusion criteria were being in the aforementioned age ranges; being diagnosed with schizophrenia by a psychiatrist and following the diagnosing criteria of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), being hospitalized in Razi Psychiatric Hospital, and diagnosed with schizophrenia for at least two years; receiving antipsychotics polypharmacy, like Largactile (500 mg/d). The exclusion criteria consisted of the lack of access to the complete medical record of the patient at the healthcare center and incomplete demographic data questionnaires.

The study participants’ demographic characteristics were collected using a demographic data questionnaire. Additionally, their medical records were evaluated in terms of comorbid disorders and non-psychiatric medicine use patterns (polypharmacy). The obtained data were analyzed in SPSS by descriptive tests, including frequency and percentage, to present between-group differences of polypharmacy and the comorbidity profiles.

3. Results

The study was conducted on 395 patients diagnosed with schizophrenia. According to Table 1, the frequency of schizophrenia disorder was higher in males aged ≥65 years. The data presented in Table 2 suggest that the comorbidity frequency of non-psychiatric disorders was higher in the elderly, compared to non-elderly patients. Table 2 also reveals that the most prevalent comorbid disorders in the elderly subjects were musculoskeletal, cardiovascular, and metabolic disorders; whereas, neurological, respiratory, and dermatological diseases had the least frequency rates among them. In addition, the data presented in Table 2 demonstrate that the frequency of non-psychiatric polypharmacy was more considerable in the subjects older than 65 years. Eventually, as Table 2, the frequency of comorbid non-psychiatric disorders was higher in patients aged ≥65 years. As Table 3 reflects, the prevalence of non-psychiatric medicine use was mainly higher in elderly patients. Table 4 indicates that the distribution frequency of non-psychiatric medicine types in the elderly (e.g. aspirin, heart disease medications, hypertension medications, etc.) and non-elderly patients (e.g. anemia medications, antibiotics, anticonvulsants, etc.) was not similar.

4. Discussion

The current study explored the comorbid profile and the pattern of non-psychiatric medicine use (polypharmacy) between elderly and non-elderly patients with schizophrenia. The achieved demographic data of the studied subjects suggested that out of 395 surveyed patients, the number of male and female schizophrenic patients aged ≥65 years were 76(58.2%), and 55(41.98%), respectively. The same rate was 196(74.24%) for male and 68(25.76%) for female patients with ≤65 years of age. Therefore, the frequency rate of schizophrenia disorder was higher in males aged ≥65 years. This finding is consistent with prior evidence, suggesting gender differences in terms of age [7].

In addition, the frequency of non-psychiatric disorders was higher in the elderly, compared to non-elderly patients. This is because 103(78.63%) schizophrenia patients of ≥65 years and only 22(8.33%) schizophrenia patients aged ≤65 years were diagnosed with non-psychiatric comorbidities. Cohen et al. reported similar findings in this area. They highlighted extensive medical care require-
Table 2. The frequency of non-psychiatric disorders, their types, as well as polypharmacy and comorbid non-psychiatric disorders

| Non-psychiatric Disorder       | No. (%) | Schizophrenia Patients ≥65 Years | Schizophrenia Patients ≤65 Years |
|--------------------------------|---------|----------------------------------|----------------------------------|
| Yes                            | 103 (78.63) | 22 (8.33)                        |                                  |
| No                             | 28 (21.37)  | 242 (91.67)                      |                                  |
| Total                          | 131 (100)   | 264 (100)                        |                                  |
| Musculoskeletal disorders      | 72 (54.97)  | 12 (4.54)                        |                                  |
| Cardiovascular disorders       | 45 (35.35)  | 9 (3.40)                         |                                  |
| Metabolic disorders            | 34 (25.95)  | 8 (3.03)                         |                                  |
| Hematological disorders        | 31 (33.66)  | 6 (2.27)                         |                                  |
| Endocrine disorders            | 14 (10.69)  | 6 (2.27)                         |                                  |
| Digestive disorders            | 10 (7.63)   | 3 (1.14)                         |                                  |
| Neurological disorders         | 5 (3.82)    | 2 (0.75)                         |                                  |
| Respiratory disorders          | 1 (0.76)    | 1 (0.38)                         |                                  |
| Dermatological disorders       | 1 (0.76)    | 1 (0.38)                         |                                  |
| 5 medications                 | 12 (9.16)   | 0                                |                                  |
| 4 medications                 | 16 (12.21)  | 0                                |                                  |
| 3 medications                 | 20 (15.27)  | 1 (0.38)                         |                                  |
| 2 medications                 | 35 (26.71)  | 5 (1.89)                         |                                  |
| 1 medication                  | 23 (17.56)  | 17 (6.44)                        |                                  |
| No medications                | 25 (19.08)  | 241 (91.29)                      |                                  |
| Total                          | 131 (100)   | 264 (100)                        |                                  |
| 4 disorders                   | 21 (16.03)  | 0                                |                                  |
| 3 disorders                   | 28 (21.38)  | 0                                |                                  |
| 2 disorders                   | 30 (22.90)  | 8 (3.03)                         |                                  |
| 1 disorder                    | 24 (18.32)  | 14 (5.30)                        |                                  |
| No disorder                   | 28 (21.37)  | 242 (91.67)                      |                                  |
| Total                          | 131 (100)   | 264 (100)                        |                                  |
ments, as a result of high comorbid disorder rates in older schizophrenic patients. They also believed that significant medical comorbidities might contribute to a higher mortality rate in this group, compared to the general population [8]. Our results are also consistent with those of Jeste and colleagues, who concluded that “elderly patients are especially likely to have comorbid disorders” [6]. These data reflect the necessity to consider and take adequate measures in terms of managing comorbidities in this population.

The obtained data revealed that the most prevalent comorbid disorders in the aging schizophrenia samples were musculoskeletal 72(54.97%), cardiovascular 45(35.35%), and metabolic disorders 34(25.95%); however, neurological 5(3.82), respiratory 1(0.76%), and dermatological 1(0.76%) diseases were least prevalent conditions among them. These findings are in contrast with those of Jeste and colleagues. In their meta-analysis, they mainly signified substance abuse, cognitive impairment, and neurological disorders, as the comorbidities of this disorder [9]. On the other hand, the obtained results are consistent with those of Falkai et al., stating that the long-term consumption of antipsychotics may result in the development of metabolic syndrome in schizophrenia patients [10].

According to the results, the prevalence of comorbid non-psychiatric disorders was higher in patients aged ≥65 years (4 comorbid disorders: 21 people (16.03%)). Additionally, the prevalence of non-psychiatric medicine use was significantly higher in elderly patients (106 (80.92%)). These findings are in line with the prior research that indicated a correlation between polyphar-

| Receiving Non-psychiatric Medications | No. (%) | Schizophrenia Patients ≥65 years | Schizophrenia Patients ≤65 years |
|--------------------------------------|---------|---------------------------------|---------------------------------|
| Yes                                  | 106 (80.92) | 23 (8.71)                      |                                 |
| No                                   | 25 (19.08)  | 241 (91.29)                     |                                 |
| Total                                | 131 (100)   | 264 (100)                       |                                 |

| Non-psychiatric Medication Type       | No. (%) | Schizophrenia Patients ≥65 Years | Non-psychiatric Medication Type | No. (%) | Schizophrenia Patients ≤65 years |
|---------------------------------------|---------|---------------------------------|---------------------------------|---------|---------------------------------|
| Aspirin                               | 54 (41.22) | Anemia medications              | 10 (3.78)                      |         |                                 |
| Heart disease medications             | 45 (34.35) | Antibiotics                     | 5 (1.89)                       |         |                                 |
| Lipid-lowering medications            | 32 (24.43) | Anticonvulsants                 | 4 (1.51)                       |         |                                 |
| Vitamin supplementations              | 21 (16.03) | Diabetes medications            | 4 (1.51)                       |         |                                 |
| Anemia medications                    | 14 (10.69) | Lipid-lowering medications      | 3 (1.14)                       |         |                                 |
| Diabetes medications                  | 13 (9.92)  | Thyroid disorder medications    | 2 (0.76)                       |         |                                 |
| Thyroid disorder medications          | 13 (9.92)  | Heart disease medications       | 2 (0.76)                       |         |                                 |
| Calcium supplementation               | 11 (8.40)  | Hypertension medications        | 1 (0.38)                       |         |                                 |
| Hypertension medications              | 9 (6.87)   | Calcium supplementation         | 1 (0.38)                       |         |                                 |
| Digestive diseases medications        | 8 (6.11)   | Digestive diseases medications  | 1 (0.38)                       |         |                                 |
| Parkinson’s disease medications       | 5 (3.82)   | Vitamin supplementations        | 1 (0.38)                       |         |                                 |
| Respiratory medications               | 1 (0.76)   |                                 |                                 |         |                                 |
Polypharmacy and numerous adverse medical conditions [11-13]. The obtained data are also consistent with the study by Mannucci et al. that documented an association between polypharmacy (the constant use of ≥5 medications) and prescription and intake errors; poor compliance; expanded risks of drug-drug interactions; adverse related effects; re-hospitalization; and even mortality [14].

We also investigated the distribution frequency of non-psychiatric medicine types in the elderly (e.g. aspirin: 54 (41.22%), heart disease medications: 45(34.35%), lipid-lowering medications: 32(24.43%)) and non-elderly schizophrenia patients (e.g. anemia medications: 10(3.78%), antibiotics: 5(1.89%), anticonvulsants: 4(1.51%). The studied groups were not similar in this aspect, too.

Eventually, evaluating the frequency of non-psychiatric polypharmacy revealed greater rates in the subjects with ≥65 years of age. The obtained related data were as follows: 5 medications: 12 people (9.16%); 4 medications: 16(12.21%); 3 medications: 20(15.27%); 2 medications: 35(26.71%); 1 medication: 23(17.56%), and no other medications: 25(19.08%) in the elderly subjects. While the majority of non-elderly individuals 241(91.29%) reported no consumption of non-psychiatric medications.

Pharmacotherapy has always been associated with trial and error; thus, scientists and practitioners must continuously review the prescribed effectiveness and adverse effects of pharmaceuticals. Such reviews must be performed in respect of therapeutic effects, as well as the patients’ condition (disorder’s severity, etc.) and treatment prognosis [15]. In summary, the co-prescription of medical and psychiatric medications leads to medication interactions and the correlated adverse effects of polypharmacy.

The limitations of the present research naturally include the following matters: The current research was conducted in a single center; thus, the obtained data must be cautiously generalized to patients with diverse backgrounds. Because of the cross-sectional nature of the research, researchers could not provide the cause-effect relationship between symptoms and other variables in a longitudinal manner. Therefore, further research is recommended to compare the elderly and non-elderly in a more comprehensive manner.

5. Conclusion

In schizophrenic patients, the old age period is associated with more comorbid disorders, compared to their healthy counterparts. Such comorbid profile is similar to other patients; e.g. the most prevalent comorbidities were musculoskeletal, cardiovascular, and metabolic disorders. Polypharmacy is a medical problem in the elderly, with numerous adverse effects. The adjunct consumption of psychiatric medications with the non-psychiatric ones highlights the vital phenomena of pharmacological interactions and the associated adverse effects of polypharmacy.

Ethical Considerations

Compliance with ethical guidelines

All study procedures involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Also, informed consent was obtained from all study participants.

Funding

This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

Authors’ contributions

All authors contributed in preparing this article.

Conflict of interest

The authors declare no competing interests.

Acknowledgments

The authors would like to acknowledge the cooperation of all the patients and Medical Centers that contributed to this work.

References

[1] Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018; 17(2):149-60. [DOI:10.1002/wps.20516] [PMID] [PMCID]

[2] Fatima A, Barkat U, Mahmood KT, Zaka M. Schizophrenia in elderly patients. Journal of Pharmaceutical Sciences and Research. 2011; 3(1):952-60. https://www.researchgate.net/publication/288157837

[3] Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidae-
Hendrie HC, Lindgren D, Hay DP, Lane KA, Gao S, Purnell C, et al. Comorbidity profile and healthcare utilization in elderly patients with serious mental illnesses. The American Journal of Geriatric Psychiatry. 2013; 21(12):1267-76. [DOI:10.1016/j.jagp.2013.01.056] [PMID] [PMCID]

Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience. 2011; 261(2):139-43. [DOI:10.1007/s00406-010-0116-z] [PMID]

Hendrie HC, Lindgren D, Hay DP, Lane KA, Gao S, Purnell C, et al. Comorbidity profile and healthcare utilization in elderly patients with serious mental illnesses. The American Journal of Geriatric Psychiatry. 2013; 21(12):1267-76. [DOI:10.1016/j.jagp.2013.01.056] [PMID] [PMCID]

Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience. 2011; 261(2):139-43. [DOI:10.1007/s00406-010-0116-z] [PMID]

[9] Jeste DV, Maglione JE. Treating older adults with schizophrenia: Challenges and opportunities. Schizophrenia Bulletin. 2013; 39(5):966-8. [DOI:10.1093/schbul/sbt043] [PMID] [PMCID]

Falkai P, Möller HJ. The functional sequelae of schizophrenia: Consequences of long-term pharmacotherapy and the neurobiology of addiction. European Archives of Psychiatry and Clinical Neuroscience; 2011; 261:83-4. [DOI:10.1007/s00406-011-0190-x] [PMID] [PMCID]

Gurwitz JH. Polypharmacy: A new paradigm for quality drug therapy in the elderly? Archives of Internal Medicine. 2004; 164(18):1957-9. [DOI:10.1001/archinte.164.18.1957] [PMID]

Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: How well can it be measured and optimised? The Lancet. 2007; 370(9582):173-84. [DOI:10.1016/S0140-6736(07)61091-5]

Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology. 2004; 57(1):6-14. [DOI:10.1046/j.1365-2125.2003.02007.x] [PMID] [PMCID]

Mannucci PM, Nobili A, Pasina L, REPOSI Collaborators. Polypharmacy in older people: Lessons from 10 years of experience with the REPOSI register. Internal and Emergency Medicine. 2018; 13(8):1191-200. [DOI:10.1007/s11739-018-1941-8] [PMID]

Pare CM. Unwanted effects of long-term medication in schizophrenia and depression. Pharmakopsychiatrie, NeuroPsychopharmakologie. 1976; 9(4):187-92. [PMID]
